Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research, published at the ATS 2025 International ...

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

aTyr Pharma, Inc. announced it will present three posters at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, showcasing its lead candidate efzofitimod, currently ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS ...

NEW YORK & BASEL, Switzerland--(BUSINESS WIRE)--Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare autoimmune and inflammatory diseases, today announced ...

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients receiving efzofitimod vs. placebo were steroid-free with a stable/improved King ...

A new study from researchers at National Jewish Health and collaborating institutions has found that different patterns seen on lung scans can signal how severe sarcoidosis may be, and how it affects ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

A new study by researchers at National Jewish Health and collaborating institutions has found that different patterns seen on lung scans can signal how severe sarcoidosis may be, and how it affects ...

Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator ...

The study did not meet the primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48. Topline data were announced from a phase 3 trial evaluating efzofitimod in ...

Shares of aTyr Pharma extended a rally into a second session Tuesday, propelled higher after the biopharma company released promising results about a lung-disease treatment from an early-stage ...